NCT04066530View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of AD-203

PHASE3CompletedINTERVENTIONAL
Enrollment

475

Participants

Timeline

Start Date

September 23, 2019

Primary Completion Date

February 26, 2020

Study Completion Date

February 26, 2020

Conditions
Acute GastritisChronic Gastritis
Interventions
DRUG

AD-203

AD-203 administered two times daily for two weeks

DRUG

Mucosta tab.

Mucosta tab. administered three times daily for two weeks

Trial Locations (1)

Unknown

Korea University Guro Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT04066530 - A Study to Evaluate the Efficacy and Safety of AD-203 | Biotech Hunter | Biotech Hunter